Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase NA 3Phase 3 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Lymphoma, Follicular 1Alzheimer Disease 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 361Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Rosiglitazone × Clear all
NCT00428090 2017-05-19

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

GlaxoSmithKline

Phase 3 Completed
862 enrolled 36 charts
Lymphoid

Alzheimer Disease, Lymphoma, Follicular

NCT00182052 2013-05-23

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Massachusetts General Hospital

Phase 3 Completed
100 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡